[Study on inhibitory effect of medicated serum of SLW on estrogen production by human endometrial cells of endometriosis].
OBJECTIVE
To explore the mechanism of inhibitory effect of SLW on estrogen production by endometrial cells of endometriosis.


METHODS
After the model of eutopic primary cultured endometrial cells of endometiosis and hysteromyoma in vitro was successfully established, the changes of steroidgenic factor-1 (SF-1), chicken ovalbumin upstream-transcription factor (COUP-TF), 17-beta-hydroxysteroid dehydrogenase 1 (17-beta-HSD1) and 17-beta-hydroxysteroid dehydrogenase 2 (17-beta-HSD2) mRNA were detected by RT-PCR before and after treatment of medicated serum of SLW. The changes of SF-1 and COUP-TF protein were also observed by western blot synchronously according to the same treatment method mentioned-above. Meanwhile ,the data of hysteromyoma group was obtained from the above experiments.


RESULTS
The expression of SF-1 mRNA and protein, 17-beta-HSD1 mRNA was weak, but COUP-TF mRNA and protein, 17-beta-HSD2 mRNA was remarkable in Hysteromyoma endometrium, as compared with those of endometiosis ,which was taken as control group (P<0.01). After the 48 hours' treatment of medicated serum of 5.0, 2.5 g kg(-1) d(-1) of SLW , the expression of COUP-TF mRNA and protein, 17beta-HSD2 mRNA was found significantly increased, but SF-1 mRNA and protein, 17-beta-HSD 1 mRNA was decreased in contrast to the control group (P <0.01 or P <0.05). Although the expresson of COUP-TF mRNA and protein was increased, SF-1 protein and 17-beta-HSD1 mRNA was decreased in 1.25 g kg(-1) d(-1) medicated serum group ,compared with those of the control group (P <0.01), the low dose group had no apparent inhibitory effect on the expression of SF-1, 17-beta-HSD2 mRNA.


CONCLUSIONS
The medicated serum of SLW could inhibit the secretion of estradiol in eutopic endometrial cells of endometiosis, and its mechanism might be associated with combined action of inhibiting expression of SF-1, 17-beta-HSD1 and up-regulating expression of COUP-TF, 17-beta-HSD2.
Li
Ao
A
College of Pharmacy, Chongqing University of Medical Science, Chongqing 400016, China.
Xu
Xiao-Yu
XY
Wang
Hui
H
Chen
Gang
G
D015067:17-Hydroxysteroid Dehydrogenases / Q000235:genetics; D000328:Adult; D000818:Animals; D051836:COUP Transcription Factors / Q000235:genetics; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004715:Endometriosis / Q000097:blood / Q000378:metabolism* / Q000473:pathology*; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D004960:Estradiol Dehydrogenases; D004967:Estrogens / Q000096:biosynthesis*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008875:Middle Aged; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D044967:Serum / Q000737:chemistry*; D054339:Steroidogenic Factor 1 / Q000235:genetics
D051836:COUP Transcription Factors; D004365:Drugs, Chinese Herbal; D004967:Estrogens; C515057:NR5A1 protein, human; D012333:RNA, Messenger; D054339:Steroidogenic Factor 1; D015067:17-Hydroxysteroid Dehydrogenases; C044256:3 (or 17)-beta-hydroxysteroid dehydrogenase; D004960:Estradiol Dehydrogenases; C523763:HSD17B2 protein, human